1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Trypanosomiasis - Pipeline Review, H2 2013

Trypanosomiasis - Pipeline Review, H2 2013

  • December 2013
  • -
  • Global Markets Direct
  • -
  • 31 pages

Trypanosomiasis - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Trypanosomiasis - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Trypanosomiasis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Trypanosomiasis. Trypanosomiasis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Trypanosomiasis.
- A review of the Trypanosomiasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Trypanosomiasis pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Trypanosomiasis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Trypanosomiasis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Trypanosomiasis - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Trypanosomiasis Overview 6
Therapeutics Development 7
Pipeline Products for Trypanosomiasis - Overview 7
Pipeline Products for Trypanosomiasis - Comparative Analysis 8
Trypanosomiasis - Therapeutics under Development by Companies 9
Trypanosomiasis - Therapeutics under Investigation by Universities/Institutes 10
Trypanosomiasis - Pipeline Products Glance 11
Early Stage Products 11
Trypanosomiasis - Products under Development by Companies 12
Trypanosomiasis - Products under Investigation by Universities/Institutes 13
Trypanosomiasis - Companies Involved in Therapeutics Development 14
iBio, Inc. 14
Panacela Labs, Inc. 15
Trypanosomiasis - Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Target 17
Assessment by Mechanism of Action 18
Assessment by Route of Administration 19
Assessment by Molecule Type 20
Assessment by Therapeutic Class 22
Drug Profiles 24
Subunit Vaccine For Trypanosomiasis - Drug Profile 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
Xenomycin - Drug Profile 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
Cysteine Proteases Inhibitors - Drug Profile 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
Drug For Parasitic Diseases - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
Nitrobenzyl Phosphoramide Mustards - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
Trypanosomiasis - Recent Pipeline Updates 29
Appendix 30
Methodology 30
Coverage 30
Secondary Research 30
Primary Research 30
Expert Panel Validation 30
Contact Us 31
Disclaimer 31



List of Tables

Number of Products under Development for Trypanosomiasis, H2 2013 7
Number of Products under Development for Trypanosomiasis - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Number of Products under Investigation by Universities/Institutes, H2 2013 10
Comparative Analysis by Early Stage Development, H2 2013 11
Products under Development by Companies, H2 2013 12
Products under Investigation by Universities/Institutes, H2 2013 13
Trypanosomiasis - Pipeline by iBio, Inc., H2 2013 14
Trypanosomiasis - Pipeline by Panacela Labs, Inc., H2 2013 15
Assessment by Monotherapy Products, H2 2013 16
Number of Products by Stage and Target, H2 2013 17
Number of Products by Stage and Mechanism of Action, H2 2013 18
Number of Products by Stage and Route of Administration, H2 2013 19
Number of Products by Stage and Molecule Type, H2 2013 21
Number of Products by Stage and Therapeutic Class, H2 2013 23
Trypanosomiasis Therapeutics - Recent Pipeline Updates, H2 2013 29



List of Figures

Number of Products under Development for Trypanosomiasis, H2 2013 7
Number of Products under Development for Trypanosomiasis - Comparative Analysis, H2 2013 8
Number of Products under Investigation by Universities/Institutes, H2 2013 10
Comparative Analysis by Early Stage Products, H2 2013 11
Assessment by Monotherapy Products, H2 2013 16
Number of Products by Top 10 Molecule Type, H2 2013 20
Number of Products by Stage and Top 10 Molecule Type, H2 2013 21
Number of Products by Top 10 Therapeutic Class, H2 2013 22
Number of Products by Stage and Top 10 Therapeutic Class, H2 2013 23



Companies Mentioned

iBio, Inc.
Panacela Labs, Inc.

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016 Summary Global Markets ...

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - Pipeline Review, H2 2016

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) ...

N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Pipeline Review, H2 2016

N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘N-Formyl ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.